One thing I have noticed at some of the support groups I run is that there seems to be a very uneven distribution of when men start taking Zoledronic Acid (ZA). Hormone therapy (ADT) has many negative side effects and the loss of bone mineral density (thinning of the bones) that ZA (and similar drugs) [...]
Sequencing of the various new advanced prostate cancer treatments remains a hot topic in our community. What treatment should come first and will the combination of various treatments be even more effective? These types of questions are constantly buzzing around us and they will continue to as long as we develop new treatments. The only [...]
Ra-223 (Alpharadin)is an alpha-pharmaceutical targeting bone metastases (mets) with high-energy, short-range (< 100 ?m) alpha-particles. Currently it has been submitted to the FDA for approval, which we hope will happen by August 2013. In the phase 3, double-blind, randomized, multinational ALSYMPCA study, Ra-223 significantly improved overall survival (OS) in men with castrate resistant advanced prostate [...]
Another interesting research abstract presented at the Genitourinary Cancers Symposium in Orlando Florida this month found that men with prostate cancer who were on chemotherapy who had also received anticoagulant (blood-thinners) medications experienced improved overall survival rates compared to men who did not take anticoagulants drugs. This retrospective study involved the reviewed of the medical [...]
Ra-223 is an investigational alpha-pharmaceutical targeting bone metastases (mets) with high-energy, short-range alpha-particles. The recently completed phase 3, double-blind, randomized, multinational ALSYMPCA study showed that Ra-223 significantly improved over all survival (OS) in CRPC men with bone mets by a median increase of 3.6 months compared with placebo (median OS: 14.9 vs 11.3 mo; P [...]